Why the Iluka Resources share price jumped 8% this morning

The Iluka Resources (ASX: ILU) share price is moving higher this morning after the release of its quarterly review showed that the company beat rutile production guidance.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Iluka Resources Limited (ASX: ILU) share price jumped 8.79% this morning after the company announced stronger-than-expected quarterly and full-year results for the period ending 31 December 2018.

For the full-year 2018, Iluka produced 348,600 tonnes of zircon, an 11.6% increase on 2017. The company had previously provided guidance of 330,000 tonnes, so the results were a well-received surprise.

2018 rutile production was down 46%, diminished by the cessation of operations at Murray Basin and incidents of strike action. The company had already revised down its rutile production estimates for 2018 after worker strikes at the Sierra Rutile project in Sierra Leone.

Revenue for 2018 was up 22%, driven primarily by a 41% increase in the weighted average price of zircon. Sales volumes were down 7% as a result of previously mentioned production constraints.

Additionally, this morning the company provided its first mineral resource estimate of rutile mineralisation at the Pejebu Deposit. Iluka estimates the deposit consists of 23.4Mt material at 0.95% in situ rutile. This works out to 0.22Mt of zircon, which is in line with previous estimates.

The Iluka Resources share price has fallen 15.7% in the last 12 months, compared to the S&P/ASX 200 which has dropped 2.31% in the period.

Motley Fool contributor Cale Kalinowski has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »